[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"postoperative-adjuvant-treatment\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:postoperative-adjuvant-treatment":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,42,85],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100627162","phase-3-postoperative-radiotherapy-combined-with-nimotuzumab-followed-by-benmelstobart-in-high-risk-patients-with-head-and-neck-squamous-cell-carcinoma-100627162",false,"NCT07445048","Postoperative Radiotherapy Combined With Nimotuzumab Followed by Benmelstobart in High-Risk Patients With Head and Neck Squamous Cell Carcinoma","A Multicenter, Randomized, Controlled, Open-Label, Phase III Clinical Trial of Postoperative Radiotherapy Combined With Nimotuzumab Followed by Benmelstobart in High-Risk Patients With Head and Neck Squamous Cell Carcinoma Who Are Ineligible for Cisplatin Chemotherapy","Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. Patients ineligible for cisplatin chemotherapy, defined as meeting any of the following:① Age \\> 70 years;② Renal insufficiency (creatinine clearance \\\u003C 50 mL\u002Fmin; criterion ⑩ below does not apply if this criterion is met);③ Severe tinnitus or hearing impairment (requiring hearing aid, or audiometry showing ≥ 25 dB loss at two consecutive frequencies);④ Unable to receive intravenous hydration (e.g., due to cardiac dysfunction or other comorbidities, as judged by the investigator);⑤ Neuropathy \\> Grade 1;⑥ Patient refusal of chemotherapy.\n3. Histologically confirmed locally advanced head and neck squamous cell carcinoma (AJCC 8th edition Stage III-IVB), including oral cavity cancer, HPV-negative\u002Funrelated oropharyngeal cancer, hypopharyngeal cancer, and laryngeal cancer.\n4. Underwent radical surgery with at least one high-risk feature:\n\n   Extracapsular extension (ECE) of lymph node metastasis; Close margin (\\\u003C 1 mm) or positive margin;\n   * 4 metastatic lymph nodes, or multiple perineural invasions.\n5. No evidence of distant metastasis on imaging.\n6. Sufficient tumor tissue available for EGFR and PD-L1 testing; for oropharyngeal cancer, HPV\u002Fp16 testing is required (testing may be waived if results are already available).\n7. Expected survival ≥ 6 months.\n8. ECOG performance status 0-1.\n9. Adequate hematologic function:\n\n   WBC ≥ 3 × 10⁹\u002FL; ANC ≥ 1.5 × 10⁹\u002FL; Platelets ≥ 100 × 10⁹\u002FL; Hemoglobin ≥ 90 g\u002FL.\n10. Adequate renal function:Serum creatinine ≤ 1.5 × ULN or creatinine clearance (CrCl) \\> 50 mL\u002Fmin (calculated by Cockcroft-Gault formula):\n\n    Female: CrCl = (140 - Age) × Weight (kg) × 0.85 \u002F (72 × Scr (mg\u002FdL)) Male: CrCl = (140 - Age) × Weight (kg) × 1.00 \u002F (72 × Scr (mg\u002FdL))\n11. Adequate hepatic function:\n\n    Total bilirubin ≤ 1.5 × ULN; AST ≤ 2.5 × ULN; ALT ≤ 2.5 × ULN.\n12. Women of childbearing potential: negative serum or urine pregnancy test within 14 days before enrollment, and agreement to use effective contraception during the study.Male subjects: use effective contraception from the start of treatment until 180 days after the last study drug administration.\n13. Voluntary participation in the study, signed written informed consent, good compliance, and willingness to comply with follow-up procedures.\n\nexclusion Criteria:\n\n1. Prior radiotherapy for head and neck cancer before enrollment.\n2. Prior treatment with similar immunological or targeted agents.\n3. Participation in another interventional clinical trial within 30 days prior to screening.\n4. Evidence of distant metastasis.\n5. History of other malignancy within the previous 5 years, except cured carcinoma in situ of the cervix, non-melanoma skin cancer, localized differentiated thyroid cancer (papillary \u002F follicular), localized prostate cancer, and ductal carcinoma in situ.\n6. Uncontrolled concurrent medical conditions (e.g., heart failure, diabetes mellitus, hypertension, thyroid disease, psychiatric disorders, etc.).\n7. Known HIV infection, active viral hepatitis, or active tuberculosis.\n8. Major surgical procedure within 30 days before the first dose of study medication, or planned major surgery during the study.\n9. Hypersensitivity to any study drug or their components.\n10. Pregnancy (confirmed by serum or urine HCG test) or lactating women; subjects of childbearing potential unwilling or unable to use effective contraception (for both male and female subjects) until at least 6 months after the last study treatment.\n11. Subjects considered inappropriate for study participation by the investigator.\n12. Subjects unwilling to participate in the study or unable to provide written informed consent.","ALL","18 Years",{"count":19,"type":20},370,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","A Multicenter, Randomized, Controlled, Open-Label, Phase III Clinical Trial.To evaluate the efficacy and safety of postoperative radiotherapy combined with Nimotuzumab followed by Benmelstobart in high-risk patients with head and neck squamous cell carcinoma who are ineligible for cisplatin chemotherapy.\n\nThe primary endpoint is disease-free survival (DFS). A total of 185 patients will be enrolled in both the study group and the control group, respectively, with a total planned enrollment of 370 patients. Enrollment is expected to be completed within 2 years, followed by a 3-year follow-up period after the last patient is enrolled.",[26,27,28],"Head & Neck Squamous Cell Carcinoma","Head & Neck Cancer","Postoperative Adjuvant Treatment","RECRUITING","2026-04-14",{"date":32,"type":33},"2026-04-17","ACTUAL",{"date":35,"type":33},"2026-03-04",{"date":37,"type":20},"2031-03-05",{"name":39,"class":40},"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":52,"briefSummary":54,"conditions":55,"keywords":62,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":84},"100598619","phase-4-effect-of-lidocaine-dexmedetomidine-on-pain-inflammation-and-oxidative-stress-after-bariatric-surgery-100598619","NCT07073846","Effect of Lidocaine-Dexmedetomidine on Pain, Inflammation, and Oxidative Stress After Bariatric Surgery.","Efficacy of Lidocaine-Dexmedetomidine Combination Therapy in Reducing Post-Operative Pain, Inflammatory Response, and Oxidative Stress in Patients Undergoing Bariatric Surgery","Inclusion Criteria:\n\n* Adults aged 18 - 60 years\n* Male or female\n* Elective laparoscopic bariatric surgery\n* Post-operative pathway: post-anaesthesia care unit (PACU) followed by standard ward, with an expected in-hospital stay ≥ 24 h\n* ASA physical-status II or III\n\nExclusion Criteria:\n\n* Use of any loco-regional anaesthetic technique during the peri-operative period (transversus abdominis plane, paravertebral, spinal, epidural, erector spinae, or other abdominal wall blocks).\n* Current substance abuse or illicit drug use.\n* Previous abdominal surgery within the last 6 months.\n* Known hypersensitivity or allergy to lidocaine, dexmedetomidine, amide local anaesthetics, or α₂-adrenergic agonists.\n* Congestive heart failure, significant bradyarrhythmia, second- or third-degree atrio-ventricular block without pacemaker, severe hypotension, or current therapy with Class I\u002FIII anti-arrhythmic drugs.\n* Estimated glomerular filtration rate (eGFR) \\\u003C 60 mL min-¹ 1.73 m-² (moderate-to-severe renal impairment).\n* Severe hepatic impairment (Child-Pugh C).\n* Pregnancy or lactation.\n* Chronic opioid consumption \\> 30 mg oral morphine equivalents per day for \\> 4 weeks\n* Active seizure disorder, myasthenia gravis, or other neurologic disease contraindicating lidocaine infusion.\n* Patient cannot communicate\n* Patient does not want to fill in the questionnaire\n* Participation in another interventional study within the past 30 days.\n* Intra-operative conversion to open surgery.\n* Insufficient biological sample for biomarker analysis.\n* Premature discontinuation of the study drug during surgery for any reason that, in the judgement of the treating anaesthesiologist or investigators, prevents adequate exposure or assessment of safety variables (e.g., major haemorrhage \\> 200 mL, anaphylactic shock, failed intubation, inability to extubate, severe metabolic\u002Frespiratory acidosis, transfer to ICU while intubated).","60 Years",{"count":51,"type":20},104,[53],"PHASE4","The goal of this randomized clinical trial is to find out whether giving an intravenous lidocaine + dexmedetomidine combination (LIDEX) during laparoscopic bariatric surgery can lower post-operative pain, inflammation, and oxidative stress in adults with obesity.\n\nThe main questions it aims to answer are:\n\n* Pain control: Does LIDEX reduce pain 24 hours after surgery, as measured with the International Pain Outcomes Questionnaire (IPOQ)?\n* Biomarkers: Does LIDEX lower blood levels of key inflammatory cytokines-interleukin-1 beta (IL-1β), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and interleukin-10 (IL-10)-and oxidative-stress markers-malondialdehyde (MDA), the reduced\u002Foxidized glutathione ratio (GSH\u002FGSSG), superoxide dismutase (SOD), and catalase-compared with the individual drugs or saline placebo?\n\nResearchers will compare four groups: lidocaine alone, dexmedetomidine alone, LIDEX, and placebo (saline solution, a look-alike substance that contains no drug) to learn which approach works best.\n\nParticipants will:\n\n* Receive an intravenous infusion of their assigned study drug(s) during surgery.\n* Provide three small blood samples (before surgery, immediately after, and three hours after).\n* Complete a short pain questionnaire (IPOQ) 24 hours after surgery.",[56,57,58,59,28,60,61],"Morbid Obesity Requiring Bariatric Surgery","Postoperative Pain","Postoperative Pain Management","Postoperative Analgesia","Postoperative Inflammatory Markers","Postoperative Inflammatory Response",[63,64,65,66,67,68,69,70,71,72,73],"Bariatric Surgery","Laparoscopic Sleeve Gastrectomy","Laparoscopic Gastric Bypass","Pain Management","Lidocaine-Dexmedetomidine","Multimodal Analgesia","Inflammatory Cytokines","Oxidative Stress","Opioid-sparing Anesthesia","Enhanced Recovery (ERAS)","Postoperarive Oxidative Stress","2025-11-26",{"date":76,"type":33},"2025-11-28",{"date":78,"type":33},"2025-10-06",{"date":80,"type":20},"2027-07-01",{"name":82,"class":83},"Instituto Mexicano del Seguro Social","OTHER_GOV",2,{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":92,"minAge":17,"maxAge":93,"enrollmentInfo":94,"targetDuration":4,"studyType":96,"phases":4,"briefSummary":97,"conditions":98,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":41},"100495443","observational-of-adjuvant-treatment-of-breast-cancer-with-liposomal-doxorubicin-regimen-100495443","NCT05731258","Observational of Adjuvant Treatment of Breast Cancer With Liposomal Doxorubicin Regimen","Clinical Observational Study of Postoperative Adjuvant Treatment of Breast Cancer With Liposomal Doxorubicin Regimen","Inclusion Criteria:\n\n1. Female, aged 18-75 years;\n2. Primary breast cancer diagnosed histopathologically;\n3. Adjuvant chemotherapy regimens include liposomal doxorubicin;\n4. ECoG PS score: 0-1 points;\n5. Left ventricular ejection fraction (LVEF) ≥ 55%;\n6. Estimated survival ≥ 6 months;\n7. Major organ function is normal, i.e. meets the following criteria:\n\n   ① And white blood cells ≥ 4.0 × 10 9 \u002F L, neutrophil count (ANC) ≥ 1.5 × 10 9 \u002FL；② Platelets ≥ 100 × 10 9 \u002FL；③ And hemoglobin ≥ 10 g \u002F dl; ④ Serum creatinine ≤ 1.5 × ⑤ the upper limit of normal (ULN) Mmol \u002F L and aspartate transaminase (AST) ≤ 2.5\n\n   × ULN；⑥ Alanine transaminase (ALT) ≤ 2.5 × ULN；⑦ Total bilirubin ≤ 1.5 × ULN；⑧ Serum creatinine ≤ 1.5 × ULN；\n8. Subjects voluntarily join this study, sign the informed consent form, have good compliance and cooperate with follow-up.\n\nExclusion Criteria:\n\n1. Pregnant, lactating patients;\n2. Breast cancer has been found to have distant metastasis;\n3. Those with peripheral nervous system disorders caused by the disease or with a history of significant mental disorders and central nervous system disorders;\n4. Those with severe infection or active peptic ulcer requiring treatment;\n5. Allergic to chemotherapy drugs;\n6. Cancer free period less than 5 years except for cured basal cell carcinoma of the skin and cured carcinoma in situ of the cervix;\n7. Severe liver disease (e.g., cirrhosis, etc.), renal disease, respiratory disease, or uncontrolled diabetes;\n8. Patients who are participating in other clinical trials or within a month.","FEMALE","75 Years",{"count":95,"type":20},150,"OBSERVATIONAL","The goal of this observational study aims to observe and evaluate the efficacy and safety of a liposomal doxorubicin containing regimen in the postoperative adjuvant treatment of breast cancer patients.",[99,100,101,102,28],"Breast Cancer","Liposomal Doxorubicin","Efficacy","Safety","2023-02-07",{"date":105,"type":33},"2023-02-16",{"date":107,"type":33},"2022-05-01",{"date":109,"type":20},"2032-10",{"name":111,"class":40},"Second Affiliated Hospital, School of Medicine, Zhejiang University"]